Advertisements



We are Sorry, This Page doesn't Exist


MoviePass" parent company wants approval for a dramatic reverse stock split of up to 1-for-500, just months after its 1-for-250 one failed to stabilize the stock (HMNY)

Hollis Johnson/Business Insider MoviePass' parent company, Helios and Matheson Analytics, will propose a reverse stock split of up to 1-for-500 to its shareholders in a special meeting next mo.....»»

Category: topSource: businessinsiderSep 17th, 2018

Spark Therapeutics Enters Oversold Territory (ONCE)

Dividend Channel.....»»

Category: topSource: redinewsSep 17th, 2018

MoviePass" parent company wants a dramatic reverse stock split

In a filing to the SEC on Monday, MoviePass' parent company Helios and Matheson stated that it will look to approve up to a 1-for-500 reverse stock split in hopes to help its failing stock during a special meeting with stockholders in October......»»

Category: topSource: moneycentralSep 17th, 2018

Sangamo Therapeutics stock drops 24% on results of cutting-edge gene-editing trial

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body......»»

Category: topSource: marketwatchSep 6th, 2018

Sangamo Therapeutics stock drops 23% on results of cutting-edge gene-editing trial

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient’s cells, completed inside the body......»»

Category: topSource: marketwatchSep 5th, 2018

Is Spark Therapeutics a Bad News Buy?

The company’s latest trial data failed to ignite a rally in its share price......»»

Category: topSource: foxnewsAug 18th, 2018

Spark Therapeutics: This Appears To Be A Dip Worth Buying

Spark Therapeutics: This Appears To Be A Dip Worth Buying.....»»

Category: topSource: seekingalphaAug 14th, 2018

Inside Twitter’s Struggle Over What Gets Banned

The social media company provided a rare look inside a policy meeting as it struggled with criticism that it left up posts from the conspiracy site Infowars and its creator, Alex Jones......»»

Category: mediaSource: nytAug 10th, 2018

‘This Is Incredibly Complex’: Inside Twitter’s Debate About What Stays on Its Site

The social media company provided a rare look inside a policy meeting as it struggled with criticism that it left up posts from the conspiracy site Infowars and its creator, Alex Jones......»»

Category: mediaSource: nytAug 10th, 2018

What Analysts Are Saying After Spark Therapeutics Q2 Report

Spark Therapeutics took a massive hit on Tuesday that wiped out about 28% of the share price in the wake of its second-quarter earnings report......»»

Category: blogSource: 247wallstAug 8th, 2018

Spark Therapeutics price target lowered to $61 from $102 at SunTrust

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2018

Why Spark Therapeutics Stock Is Getting Slammed Today

InvestorPlace - Stock Market News, Stoc.....»»

Category: topSource: investorplaceAug 8th, 2018

Spark Therapeutics price target lowered to $64 from $75 at RBC Capital

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2018

Spark Therapeutics selloff on hemophilia A data overdone, says Barclays

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2018

Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation

Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation.....»»

Category: topSource: seekingalphaAug 8th, 2018

Spark Therapeutics price target lowered to $77 from $91 at Mizuho

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2018

Spark Therapeutics downgraded to Market Perform from Outperform at BMO Capital

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 7th, 2018

Why Weight Watchers International, Tenet Healthcare, and Spark Therapeutics Slumped Today

Find out which of these stocks had the biggest losses......»»

Category: topSource: foxnewsAug 7th, 2018

Spark Therapeutics (ONCE) CEO Jeff Marrazzo on Q2 2018 Results - Earnings Call Transcript

Spark Therapeutics (ONCE) CEO Jeff Marrazzo on Q2 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaAug 7th, 2018

Brainstorm Health: Icahn Slams Cigna-Express Scripts, Female Heart Attack Patients, Spark Therapeutics Plunge

Brainstorm Health Daily: August 7, 2018 Good afternoon, readers. This is Sy. Carl Icahn has some thoughts about insurer Cigna’s proposed mega-deal with pharmacy benefits manager (PBM) Express Scripts--and he’s.....»»

Category: europeSource: fortuneAug 7th, 2018